Topics

Glioblastoma | Treatment | Radiotherapy | Radiosensitizers

Home > Publications > Topics > Glioblastoma > Treatment > Radiotherapy > Radiosensitizers

Pepper NB, Eich HT, Müther M, Oertel M, Rehn S, Spille DC, Stummer W.
ALA-RDT in GBM: protocol of the phase I/II dose escalation trial of radiodynamic therapy with 5-Aminolevulinic acid in patients with recurrent glioblastoma.
Radiat Oncol. 2024 Jan 22;19(1):11. doi: 10.1186/s13014-024-02408-7. PMID: 38254201. Interventional study protocol. ˍ

Liu M, Li T, Zhao M, Qian C, Wang R, Liu L, Xiao Y, Xiao H, Tang X, Liu H.
Nanoradiosensitizers in glioblastoma treatment: recent advances and future perspectives.
Nanomedicine (Lond). 2024 Sep 23;19(26):2229-2249. doi: 10.1080/17435889.2024.2395238. PMID: 39311492. Review˰ ˍ

Mendez JS, Cohen AL, Eckenstein M, Jensen RL, Burt LM, Salzman KL, Chamberlain M, Hsu HH, Hutchinson M, Iwamoto F, Ligon KL, Mrugala MM, Pelayo M, Plotkin SR, Puduvalli VK, Raizer J, Reardon DA, Sterba M, Walbert T, West BL, Wong ET, Zhang C, Colman H.
Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Neurooncol Adv. 2024 Nov 22;6(1):vdae202. doi: 10.1093/noajnl/vdae202. PMID: 39734810. Interventional study. ˍ

Skeie BS, Sleire L, Grüner ER, Bragstad S, Heggdal JI, Eide GE, Enger PØ.
Phase I trial combining sulfasalazine and gamma knife radiosurgery for recurrent glioblastoma.
MethodsX. 2026 Apr 22;16:103915. doi: 10.1016/j.mex.2026.103915. PMID: 42089023. Trial registration ID: NCT04205357. ˍ

Skeie BS, Craig-Craven AR, Grüner ER, Biermann M, Riemer F, Bragstad S, Sarowar S, Behbahani M, Sleire L, Schwarzlmüller T, Goplen D, Heggdal JI, Knisely JPS, Schulder M, Eide GE, Filippi CG, Enger PØ.
Phase 1 dose-escalation trial combining sulfasalazine and stereotactic radiosurgery in patients with recurrent glioblastoma.
Redox Biol. 2026 May 30;95:104241. doi: 10.1016/j.redox.2026.104241. PMID: 42229231. Trial registration ID: NCT04205357. ˍ